Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme

British Journal of Cancer
K YipJ Maher

Abstract

Prostate cancer is the most commonly diagnosed malignancy in British men. The increasing use of PSA screening test has resulted in many more patients being diagnosed with this condition. Advances in its treatment have improved the survival rate among these patients. By 2040, the prevalence of prostate cancer survivors is expected to reach 830 000. Many of them will require medical support for the management of their progressive disease or long-term toxicities from previous treatments. Successful implementation of the cancer survivorship programme among these patients depends on a good understanding of their demand on the health care system. The aim of this study is to segment the population of prostate cancer survivors into different needs groups and to quantify them with respect to their phase of care. Incidence, survival, prevalence and mortality data collected and reported by cancer registries across the United Kingdom have been used for the current study to provide indicative estimates as to the number of prostate cancer patients in each phase of the care pathway in a year. The majority of prostate cancer patients are in the post-treatment monitoring phase. Around a fifth of the patients are either receiving treatment or in...Continue Reading

References

Aug 31, 2002·Psycho-oncology·David T Eton, Stephen J Lepore
Nov 14, 2002·Family Practice·Neil C CampbellDavid Weller
Feb 1, 2003·Annals of Internal Medicine·Arlyss Anderson Rothman, Edward H Wagner
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Jan 11, 2005·BJU International·Vijay K SangarRosie A Blades
Jan 14, 2005·The New England Journal of Medicine·Vahakn B ShahinianJames S Goodwin
Aug 16, 2005·Lancet·Michel BollaUNKNOWN European Organization for Research and Treatment of Cancer
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith
Nov 18, 2006·Cancer Causes & Control : CCC·Angela B MariottoMartin Brown
Mar 21, 2008·The New England Journal of Medicine·Martin G SandaJohn T Wei
Jun 19, 2008·JAMA : the Journal of the American Medical Association·Bruce J TrockPatrick C Walsh
Jul 2, 2009·British Journal of Cancer·J MaddamsH Møller
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence KlotzAndrew Loblaw
Mar 17, 2010·BJU International·Rosaleen O'BrienUNKNOWN Prostate Cancer Follow-up Group
Nov 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shabbir M H AlibhaiGary Naglie
Dec 1, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergPeter R Carroll
Apr 27, 2011·Nature Reviews. Urology·Nathan Lawrentschuk, Laurence Klotz
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R CooperbergLaurence Klotz
Sep 3, 2011·BJU International·Claus G Roehrborn, Libby K Black
Oct 29, 2011·British Journal of Cancer·M MistryP Sasieni
Nov 9, 2011·British Journal of Cancer·J MaddamsH Møller
Nov 9, 2011·British Journal of Cancer·J Maher, H McConnell
Jun 16, 2012·European Urology·Marc A Dall'EraMark S Soloway
Jul 10, 2012·American Journal of Clinical Oncology·William M MendenhallNancy P Mendenhall
Jul 20, 2012·The New England Journal of Medicine·Timothy J WiltUNKNOWN Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group
Aug 16, 2012·British Journal of Cancer·J MaddamsH Møller
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Aug 31, 2012·The New England Journal of Medicine·Juanita M CrookLaurence Klotz
Nov 20, 2012·European Urology·Meelan BulMonique J Roobol
Jan 23, 2013·The Cancer Journal·Darren BradyJoe M O'Sullivan
Mar 12, 2013·European Urology·Elizabeth D SelvaduraiChris C Parker
Mar 21, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Caroline C HensonJohn McLaughlin
Apr 5, 2013·The New England Journal of Medicine·Maha HussainIan M Thompson
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators

❮ Previous
Next ❯

Citations

Mar 5, 2016·Expert Opinion on Therapeutic Targets·Marine J ChalanquiHelen O McCarthy
Dec 23, 2014·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Susan WilliamsonKinta Beaver
Sep 25, 2020·JCO Oncology Practice·Tahlia ScheinbergLisa G Horvath

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved